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Abstract
Background
Cystic Fibrosis (CF) is characterized by chronically inflamed airways, and inflammation
even increases during pulmonary exacerbations. These adverse events have an important
influence on the well-being, quality of life, and lung function of patients with CF. Prediction
of exacerbations by inflammatory markers in exhaled breath condensate (EBC) combined
with early treatment may prevent these pulmonary exacerbations and may improve the
prognosis.
Aim
To investigate the diagnostic accuracy of a set of inflammatory markers in EBC to predict
pulmonary exacerbations in children with CF.
Methods
In this one-year prospective observational study, 49 children with CF were included. During
study visits with an interval of 2 months, a symptom questionnaire was completed, EBC
was collected, and lung function measurements were performed. The acidity of EBC was
measured directly after collection. Inflammatory markers interleukin (IL)-6, IL-8, tumor
necrosis factor α (TNF-α), and macrophage migration inhibitory factor (MIF) were measured
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using high sensitivity bead based flow immunoassays. Pulmonary exacerbations were
recorded during the study and were defined in two ways. The predictive power of inflamma-
tory markers and the other covariates was assessed using conditionally specified models
and a receiver operating characteristic curve (SAS version 9.2). In addition, k-nearest
neighbors (KNN) algorithm was applied (SAS version 9.2).
Results
Sixty-five percent of the children had one or more exacerbations during the study. The con-
ditionally specified models showed an overall correct prediction rate of 55%. The area
under the curve (AUC) was equal to 0.62. The results obtained with the KNN algorithm were
very similar.
Conclusion
Although there is some evidence indicating that the predictors outperform random guess-
ing, the general diagnostic accuracy of EBC acidity and the EBC inflammatory markers IL-
6, IL-8, TNF-α and MIF is low. At present it is not possible to predict pulmonary exacerba-
tions in children with CF with the chosen biomarkers and the method of EBC analysis. The
biochemical measurements of EBC markers should be improved and other techniques
should be considered.
Introduction
Cystic fibrosis (CF) is the most common life-shortening genetic disease in the Caucasian popu-
lation, caused by a mutation in the cystic fibrosis transmembrane conductance regulator
(CFTR) gene [1]. There are different types of mutations in this gene, all of them leading to a
defective or absent CFTR protein [2]. The CFTR protein is expressed in the apical membrane
of epithelial cells, and a defective protein causes problems in organs with a secretory function
such as the lungs, intestines and pancreas. Hence CF is a multi-system disease. Nevertheless
the course of this progressive disease is predominantly determined by respiratory symptoms
and complications [3]. Respiratory deteriorations caused by alteration of the fragile homeosta-
sis between airway pathogens and local host defenses are termed pulmonary exacerbations
which are common in CF [4]. Pulmonary exacerbations present clinically with a variety of
symptoms such as increased cough, increased sputum production, increased dyspnea,
decreased energy level and appetite, weight loss and decreases in lung function parameters [5].
Currently these adverse events are treated with antibiotics when apparent, it is not yet possible
to predict them. This means there is often a delay in starting treatment. An earlier treatment
may positively influence the course of an exacerbation and improve long term prognosis in CF.
However, to start treatment timely, it is necessary to detect pulmonary exacerbations at a very
early stage.
Chronic inflammation of the airways is a major characteristic of CF. The inflammatory
response is excessive and dysregulated, furthermore it plays an important role in both chronic
bacterial infections and pulmonary exacerbations [6]. The CF airway contains several pro-
inflammatory mediators (like tumor necrosis factor alpha [TNF-α], interleukin [IL]-6 and IL-8
and counter-regulatory molecules like IL-10) [7]. Macrophage migration inhibitory factor
(MIF) is another pro-inflammatory cytokine important in the regulation of both the innate
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and acquired immune responses [8]. The MIF polymorphism, associated with lower promotor
activity, is associated with milder lung disease in F508del CF patients [9]. Previous research in
children with CF showed that inflammatory markers can be measured in exhaled breath con-
densate (EBC) [10]. In contrast to bronchoalveolar lavage fluid, induced sputum and endo-
bronchial biopsies, EBC is a completely non-invasive, safe and fast technique, not bearing any
health risks, and also feasible in young children [11]. In an earlier cross-sectional study in 98
children with CF and healthy controls, we found that inflammatory markers in EBC were able
to indicate presence, severity and stability of CF disease [12]. A pilot study of our group showed
that IL-6, IL-8, IL-10, TNF-α, and MIF, were predictive for exacerbations in children with CF
[13]. Therefore, we hypothesized that pulmonary exacerbations can be predicted at an early
stage by assessing the inflammatory markers IL-6, IL-8, TNF-α and MIF in EBC. The aim of
this study was to investigate the diagnostic accuracy of this set of inflammatory markers in
EBC to predict pulmonary exacerbations in children with CF.
Methods
Study design and setting
For this one-year observational cohort study (clinicaltrial.gov NCT01241890), children with
CF between 5 and 18 years were recruited from three CF centers in the Netherlands (Maas-
tricht, Amsterdam and Utrecht). Families were approached for the study by one of the pediat-
ric pulmonologists during regular hospital visits and received written and oral information.
The Medical Ethical Committee of the Maastricht University Medical Centre approved this
study. Informed consent was signed by all parents and by children aged 12 years and older.
In the Maastricht University Medical Centre enrolment started in December 2011 and fol-
low-up ended in May 2013. In the University Medical Centre Utrecht, the first children were
enrolled in January 2012 and follow-up ended in June 2013. Finally, enrolment of children in
the AmsterdamMedical Centre started in March 2012 and follow-up ended in August 2013.
Study visits were scheduled every 2 months during one year. To lessen the burden of the
study and avoid loss to follow-up, we combined study visits with regular hospital visits as
much as possible.
Patients
CF disease was defined as the presence of characteristic clinical features (persistent pulmonary
symptoms, meconium ileus, failure to thrive, steatorrhea) in combination with an abnormal
sweat test (chloride> 60mM/L) and/or two CF mutations [14].
Exclusion criteria were: 1) severe cardiac abnormalities; 2) mental disability; 3) no techni-
cally adequate performance of measurements; 4) on waiting list for lung transplantation; 5)
children colonized with Burkholderia Cepacia or Methicillin Resistant Staphylococcus Aureus;
6) participation in an intervention trial.
Study parameters
The occurrence of a pulmonary exacerbation was the primary outcome measure which was
defined in two ways: first, according to the definition used in the EPIC trial [15]; and second,
when the responsible pediatric pulmonologist started a course of therapeutic antibiotics (oral
and/or intravenous) considering the clinical symptoms as an expression of a pulmonary
exacerbation.
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The presence of an exacerbation according to the EPIC trial was established by one of the
major criteria alone, or two of the minor signs, and fulfillment of symptom duration (duration
of sign/symptoms5 days or significant symptom severity) (Table 1).
Treatment of pulmonary exacerbations during the study occurred in accordance with the
Dutch Central Guidance Committee (CBO) guideline [16], which closely resembles European
[14] and American CF guidelines [17]
During every study visit, the same measurements took place: first, children completed a
questionnaire, thereafter EBC collection took place, and finally, lung function measurements
were performed. All measurements were carried out by extensively trained members of the
research teams. The measurements were the same for all children.
Questionnaire. A questionnaire derived from the validated Dutch version of the revised
Cystic Fibrosis Questionnaire (CFQ-R) was used to evaluate symptoms [18]. At 0, 6 and 12
months the CFQ-R was completed entirely by all children. The CFQ-R consists of 35–50 items
divided into 7–9 domains (depending on age): physical functioning, energy and well-being,
emotional state, social limitations, role limitations, body image, eating disturbances, treatment
burden, and embarrassment. Furthermore, overall health perception and three symptom scales
are included: respiratory, digestive and weight. Items require either a frequency response on a
4-point scale (‘all the time’ to ‘never’), a difficulty rating on a 4-point scale (‘a lot of difficulty’
to ‘no difficulty’), a true–false rating on a 4-point scale, or the selection of a statement that
describes the patient (on a 3- or 4-point scale). The scores range from 0 to 100 with higher
scores corresponding to higher quality of life.
Exhaled Breath Condensate (EBC). Children breathed tidally for ten minutes, while
wearing a nose-clip, through a mouthpiece connected to a two-way non-rebreathing valve
(Hans Rudolph Inc, series 1420, Kansas City, USA) into a condenser system like described pre-
viously [19]. The two-way valve and swan-neck tubing, served as a saliva trap to the condenser
system. When the child ceased the procedure, EBC was collected by pushing the plunger down-
wards and sampling in a collection tube. The glass condenser was cooled using a counter-cur-
rent circulating ice-water pump. The cooling temperature was pre-set at 0.7°C. EBC acidity
was determined without deaeration immediately after collection (handheld pH-meter, type
PH1000H, and mic-microS7 pH sensor, VWR International B.V., NL, Germany). Condensate
samples were snap-frozen using dry ice and stored at -80 degrees Celsius. Freeze-thaw cycles
between collection and chemical analysis were avoided. To determine the levels of IL-6, IL-8,
TNF-α, and MIF a commercially available high sensitivity bead-based flow immunoassays
Table 1. Definition of pulmonary exacerbation according to EPIC trial.
Major criteria
Decrease in FEV1 >10% from best baseline within past 6 months, unresponsive to beta-2 agonist
Oxygen saturation <90% on room air or >5% decline from previous baseline
New lobar inﬁltrate(s) or atelectasi(e)s on chest radiograph
Haemoptysis (more than streaks on more than one occasion in past week)
Minor criteria
Increased work of breathing or respiratory rate
New or increased adventitial sounds on lung exam
Weight loss >5% of body weight or decrease across 1 major percentile in weight percentile for age in past
6 months
Increased cough
Decreased exercise tolerance or level of activity
Increased chest congestion or change in sputum
doi:10.1371/journal.pone.0152156.t001
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were used and concentrations were calculated using BioPlex software version 5.1 (Millipore, St
Charles, MO, USA). All multiplex immunoassays were performed in 96 well format 1.2 μm fil-
ter bottom plates (Millipore, Amsterdam, The Netherlands) and a 12 point standard curve in
duplicate was included on every plate. This standard curve consisted of the calibration fluids
including two sequential dilutions to decrease the lower limit of quantification (LLoQ) of the
assay. The median LLoQ’s assessed during analysis of the EBC samples were for IL-6: 114 fg/
ml, IL-8: 25 fg/ml, TNF-α: 107 fg/ml and MIF 3710 fg/ml. In order to minimize interassay vari-
ation, positive and negative control samples were included. When fluorescence indices were
below LLoQ, but above background, concentrations of samples were calculated by extrapola-
tion. If concentrations could not be extrapolated, a concentration of 50% of the lowest mea-
sured concentration for the specific marker was imputed like described previously [20].
Lung function. The Masterscreen Pneumo (Carefusion, Houten, The Netherlands) was
used to measure dynamic lung function parameters, according to ATS/ERS standards [21].
The highest values of three technically correct performed maneuvers were used for analysis.
Recorded parameters were: Forced Expiratory Volume in 1 second (FEV1), forced vital capacity
(FVC) and maximum expiratory flow at 50% of FVC (MEF50), all expressed as a percentage of
the predicted normal value. Static lung function indices (total lung capacity [TLC], residual
volume [RV], functional residual capacity [FRC], expiratory reserve volume [ERV] and intra-
thoracic gas volume [ITGV]) were determined at 0 and 12 months by means of body plethys-
mography using the Masterscreen Body (Carefusion, Houten, The Netherlands).
Covariates. Sex, Age, colonization with Pseudomonas Aeruginosa at inclusion, the use of
prophylactic or therapeutic antibiotics, the use of corticosteroids, the time between visits and
exacerbation at previous visit were considered as covariates. Information about the use of med-
ication was checked at every study visit.
Sample size
Forty-nine children were included in this observational cohort study. Based on an assumed
prevalence of an exacerbation of 50% and assuming the worst case sensitivity and specificity of
0.50, the width of the confidence interval for sensitivity and specificity would be 0.4 (0.3–0.7).
Statistical data analysis
For the statistical data analysis, SAS software package version 9.2 was used. To assess the pre-
diction capacity of the biomarkers, a form of conditionally specified models, the so-called tran-
sition models were used. In transition models a measurement in a longitudinal sequence is
described as a function of previous outcomes and covariates [22]. In this study the probability
of a pulmonary exacerbation between the current and next visit was assessed using 2 condi-
tional models. The first model (Model 1) included the biomarkers (IL-6, IL-8, TNF-α and
MIF), pH of the EBC, lung function parameters (FEV1, FEV1% of predicted value, FVC and
FVC % of predicted value), the time between visits and the presence of exacerbation at previous
visit as predictors. The second model (Model 2) included all the predictors of the first model
and age, sex, colonization with Pseudomonas Aeruginosa at inclusion, ABPA at inclusion, use
of prophylactic antibiotics and use of inhalation corticosteroids. The data set was divided into a
training and validation data sets. The training data set, containing the information of 36 ran-
domly selected children, was used to estimate the predictive models and the predictive perfor-
mance of the models was evaluated using the information in de validation data set containing
the information of the remaining 13 children. The predictive capability of the models was pri-
marily evaluated using the area under the corresponding ROC-curves. Additionally, the per-
centage of correct predictions was assessed using the validation data set.
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Besides, the KNN algorithm was used to evaluate the predictive performance of the bio-
markers in the validation data set using the information in the training data set. KNN is a non-
parametric lazy learning algorithm [23]. The training samples are vectors of predictors or
covariates, each with a class label. The training phase of the algorithm consists only of storing
the feature vectors and class labels of the training samples.
All 49 patients were included in the statistical analysis, despite loss to follow-up or exclusion
during the study. The proportion of missing values was generally low (less than 3.5%). The
exception was pH that had about 7.6% of missing values. Only the presence of missing values
in pH was considered for the construction of the predictive model, these missing values had no
predictive value.
Results
Patients
Forty-nine children with CF were included in the study (Fig 1). One child was excluded after
10 months because of becoming a carrier ofMethicillin Resistant Staphylococcus Aureus. Six
out of the 49 children were lost to follow-up, mostly because of personal reasons (n = 5), or
because of a mild adverse effect of inhaled tobramycin (n = 1). Data of the children who were
lost to follow-up were included in the analysis (‘intention to treat’).
The mean age of the children was 10.3 years, more boys participated (63.3%) and the major-
ity of the children had a homozygous DF508 mutation (73.5%). The lung function was good
Fig 1. Consort flow diagram of the study.
doi:10.1371/journal.pone.0152156.g001
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with a mean FEV1 of 87.4% of predicted value. The nutritional status was good as reflected by
the BMI and BMI-SDS (Table 2). All children were included in the statistical analysis. Eighty-
four percent of the children were evaluated seven times, 2 of the drop-outs had only 1
measurement.
Pulmonary exacerbations
When the EPIC trial definition for a pulmonary exacerbation was used, 32 children (65%) had
1 or more exacerbations during the study (Table 3). The prescription of therapeutic antibiotics
by the pediatrician increased the percentage of children with exacerbation(s) to 88%.
Description of biomarkers in EBC
There was a great variability in concentrations of measured biomarkers in EBC. The distribu-
tion of EBC acidity, and concentration of EBC biomarkers is given in Table 4.
Diagnostic accuracy of biomarkers in EBC
The best predictive results were obtained using the most complex Model 2. The estimated
parameters for this model are provided in S1 Table. This transition model correctly predicted
55% of the events (exacerbations or no exacerbations) in the validation dataset (Table 5). The
prediction of an exacerbation was based on the probability of an exacerbation obtained from
the prediction model with the probability> 0.5 as a cut-off point.
However, the analysis of the ROC curve showed that the best predictions were obtained
using a threshold of about 0.48 for the predictive probability of exacerbation, which led to a
sensitivity of 0.70 and a specificity of 0.50. Thus, in the best scenario, the model would detect
70% of the exacerbations but would fail to predict absence of an exacerbation in 50% of the
time. The predictive model (with threshold 0.48) led to an area under the curve of 0.62 (CI
0.49–0.75) (Fig 2).
Table 2. Baseline characteristics.
Characteristic Total (n = 49)
Age, mean (SD) 10.3 (3.6)
Male sex, N (%) 31 (63.3)
Homozygous F508del, N (%) 36 (73.5)
Pseudomonas Aeruginosa at inclusion*, N (%) 15 (30.6)
Allergic Bronchopulmonary Aspergillosis (ABPA) at inclusion, N (%) 2 (4.0)
Pulmonary Exacerbations in 2 years before inclusion, N (%) 23 (46.9)
BMI, median (IQR) 16.8 (16.0–18.1)
BMI-SDS, mean (SD) 0.14 (0.83)
FEV1% predicted value, mean (SD) 87.4 (18.1)
FEV1/FVC, mean (SD) 0.80 (0.1)
TLC % predicted value, mean (SD) (n = 38) 101.1 (12.0)
RV % predicted value, mean (SD) (n = 37) 130.9 (42.7)
Prophylactic antibiotics, N (%) 28 (57.1)
Inhalation corticosteroids, N (%) 16 (32.7)
BMI, body mass index; FEV1, Forced Expiratory Volume in 1 second; FVC, Forced Vital Capacity; RV,
Residual Volume; TLC, Total Lung Capacity.
* treated because of presence in sputum.
doi:10.1371/journal.pone.0152156.t002
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The results obtained when the KNN algorithm was used were very similar. The KNN algo-
rithm correctly predicted 59% of the events. If the second definition of a pulmonary exacerba-
tion (when the responsible pediatric pulmonologist started a course of therapeutic antibiotics)
was used, the overall correct prediction of the transitional model was 49% and the KNN algo-
rithm predicted correctly 54% of the events.
Discussion
In this study, we assessed the diagnostic accuracy of a set of biomarkers in EBC to predict pul-
monary exacerbations in children with CF. Overall, we found low predictive power of the EBC
acidity and the inflammatory markers IL-6, IL-8, TNFα and MIF. Neither the definition of
exacerbations (the EPIC trial definition versus the prescription of therapeutic antibiotics by the
pediatrician) nor the statistical method (transition models versus KNN algorithm) did signifi-
cantly affect the results. At present, it is not possible to predict pulmonary exacerbations in
children with CF by means of the chosen biomarkers and methods.
To our knowledge, only Horak et al performed a longitudinal study to investigate if an
inflammatory marker, EBC nitrite, was helpful in monitoring lung disease in children with CF.
They found that EBC nitrite could not predict pulmonary exacerbations or changes in pulmo-
nary function or clinical and radiological scores [24]. Others have assessed inflammatory
markers in EBC before and after treatment of pulmonary exacerbations. Bodini et al found that
IL-8 EBC levels decreased and EBC acidity increased after antibiotic treatment of a pulmonary
exacerbation [25]. In the study of Colombo et al., multiple biomarkers including IL-6, IL-8 and
TNFα were measured in EBC before, during and after an acute exacerbation in adult CF
patients [26]. Although IL-8 was positively correlated with CRP at the start and after 15 days of
treatment, in a multivariate regression analysis, no significant associations between biomarkers
in EBC and clinical variables were found [26]. Ojoo et al reported that EBC acidity was signifi-
cantly lower during an exacerbation compared to stable disease [27]. In addition, inflammatory
Table 3. Number and percentages of children with pulmonary exacerbations (EPIC trial definition)
during study.
Number of pulmonary exacerbations Frequency Percentage
0 17 34.7
1 12 24.5
2 8 16.3
3 6 12.2
4 3 6.1
5 3 6.1
doi:10.1371/journal.pone.0152156.t003
Table 4. Acidity of EBC and concentrations of biomarkers in EBC.
Variable Minimum Maximum Median Mean SD
pH 0 7.2 6.0 5.95 0.59
IL-6 (fg/ml) 0.35 107.0 0.35 3.25 10.08
IL-8 (fg/ml) 0.45 4710.80 0.45 24.09 272.16
TNF-α (fg/ml) 1.90 132.60 1.90 13.38 25.06
MIF (fg/ml) 92.53 291391.08 344.67 3141.64 17138.79
IL-6, interleukin-6; IL-8, interleukin-8; MIF, macrophage migration inhibitory factor; TNF-α, tumor necrosis factor α
doi:10.1371/journal.pone.0152156.t004
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markers have been studied in induced sputum. Liou et al. reported that high mobility group
box-1 protein (HMGB-1), a novel inflammatory cytokine, predicted time-to first acute pulmo-
nary exacerbation and number of future exacerbations within 5 years [28]. In summary, bio-
markers in EBC and induced sputum have been studied but results are variable and not yet
applicable to clinical practice.
An important strength of our study is its prospective and longitudinal character: we have
followed 49 children with CF during one year. We obtained EBC every 2 months, and recorded
all exacerbations to investigate the predictive power of inflammatory markers in EBC. Further-
more, we used advanced statistical methods, transitional models and KNN algorithm, which
take recurrent and dependent findings into account, and in this way fits the longitudinal nature
of our study. This in contrast to other predictive models that presume one condition or finding
independently leads to one outcome. Another strength is the use of two definitions of a pulmo-
nary exacerbation as primary outcome measure, which minimizes information bias as a result
of misclassification. If we had only used the stringent definition of the EPIC trial, we might
have missed mild exacerbations, and incorrectly classified children as being stable when they
were not. However, the use of two definitions accounts for heterogeneity of this primary out-
come measure.
There are several explanations that could account for not being able to predict pulmonary
exacerbations with the chosen biomarkers in EBC. First, in comparison with earlier studies [12,
19, 20], we had to switch to commercially available hypersensitive kits to analyze the EBC sam-
ples because the assay we used before was no longer available. The detection of cytokines and
chemokines in EBC using this kit was lower than previously reported. Second, an explanation
for the generally low concentrations of biomarkers in EBC may be the dilution of EBC as a
medium. There are methods to correct for this dilution but each has specific disadvantages and
therefore it is not recommended [11]. Third, the results of the biochemical analysis showed a
large variability in concentrations of the measured biomarkers. This occurred in children with
exacerbations as well as in children without exacerbations. Possible explanations for this vari-
ability of concentrations could be the used assays are not developed or adjusted for EBC, and
the antibodies lack sensitivity and specificity [29]. In addition to the described factors influenc-
ing the biochemical analysis of the EBC samples, other aspects could have influenced our find-
ings. The time frame between study visits might have been too long to detect relevant changes
in biomarkers. In case we had collected EBC more frequently, it might have been easier to
detect (small) changes in inflammatory markers. Besides, the interval between sampling of
EBC and the start of a pulmonary exacerbation would have been shorter, which might have
increased the chance to find an association between the increase in inflammation and the
exacerbation. However, Sagel et al. reported biomarkers of inflammation to change over
months rather than over days or weeks [30]. Which is in line with the time for clinical decision
making whether or not to treat pulmonary exacerbations. Additionally in a comparable study
in 40 children with asthma, we found that EBC acidity and IL-5 assessed every 2 months were
Table 5. Translational model prediction of pulmonary exacerbation (EPIC trial definition).
Pulmonary exacerbation Prediction
No, n (%) Yes, n (%) Total, n (%)
No 39 (44) 8 (9) 47 (53)
Yes 32 (36) 10 (11) 42 (47)
Total 71 (80) 18 (20) 89 (100)
doi:10.1371/journal.pone.0152156.t005
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significantly related to the exacerbation rate [31]. The choice of the biomarkers in the present
study was based on the pathogenesis of CF, the possibility to measure the markers in EBC and
on previous findings of predictive ability of exacerbations in a pilot study of our group [13].
Fig 2. ROC-curve of predictive model of pulmonary exacerbations (EPIC trial definition).
doi:10.1371/journal.pone.0152156.g002
Biomarkers in Exhaled Breath Condensate Not Predictive for Exacerbations in Cystic Fibrosis
PLOS ONE | DOI:10.1371/journal.pone.0152156 April 6, 2016 10 / 13
Finally, our sample size was rather small, nonetheless, a larger group would probably not have
improved our findings since not even a predictive trend was visible.
Although the collection of EBC is non-invasive, safe, fast and EBC originates directly from
the (in this case chronically inflamed) airways, inflammatory markers in EBC currently do not
contribute to the prediction of pulmonary exacerbations in children with CF. Future research
should focus on development of EBC-specific sensitive assays for analysis of inflammatory
markers in EBC that can cope with the strong dilution of EBC and the possible matrix effects.
Furthermore, the potential of other techniques to analyze EBC like Nuclear Magnetic Reso-
nance (NMR) spectroscopy, metabolomic profiling, gene expression or microbiome analyses
should be explored.
In conclusion, we found that 2-monthly assessed inflammatory markers (IL-6, IL-8, TNFα
and MIF) in EBC and acidity of EBC were not able to predict pulmonary exacerbations in chil-
dren with CF. This may well be due to methodological problems concerning the biochemical
analysis of EBC. Considering chronic airway inflammation is a major hallmark of CF and pul-
monary exacerbations negatively influence the prognosis, it would be a big step forward to be
able to measure this airway inflammation (directly and non-invasively) and predict upcoming
exacerbations.
Supporting Information
S1 Table. Performance of acidity of EBC, inflammatory markers in EBC and covariates in
prediction of pulmonary exacerbations.
(DOCX)
Acknowledgments
The authors thank all children and parents for taking part in this study. Besides, this study
could not be carried out without the outstanding efforts of Sylvia Esten, Sabine Michel, Eltje
Bloemen, Margreet Polman, Saeeda Lone and Nora Adriaens who were responsible for the per-
formance of the clinical visits. We also want to thank the medical students Myrthe Kersemae-
kers, Sanne Vaassen, Myrthe Berkhof, Sjoerd Gulikers and Elles Broen for their great assistance
during this study. Ben de Jong thank you for the chemical analysis of exhaled breath conden-
sate and help with interpretation of the data.
Author Contributions
Conceived and designed the experiments: MVH GWQJ ED GR. Performed the experiments:
MVH GWKDWWVAQJ ED GR. Analyzed the data: MVH AA GW BWQJ ED GR. Contrib-
uted reagents/materials/analysis tools: MVH AA GWKDWWVAHH BWQJ ED GR. Wrote
the paper: MVH AA GWKDWWVA HH BWQJ ED GR.
References
1. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009; 373(9678):1891–904. doi: 10.1016/S0140-
6736(09)60327-5 PMID: 19403164
2. Ratjen F. Recent advances in cystic fibrosis. Paediatr Respir Rev. 2008; 9(2):144–8. doi: 10.1016/j.
prrv.2008.01.004 PMID: 18513677
3. Zemanick ET, Harris JK, Conway S, Konstan MW, Marshall B, Quittner AL, et al. Measuring and
improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.
J Cyst Fibros. 2010; 9(1):1–16. doi: 10.1016/j.jcf.2009.09.003 PMID: 19833563
4. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, et al. Defining a pul-
monary exacerbation in cystic fibrosis. J Pediatr. 2001; 139(3):359–65. PMID: 11562614
Biomarkers in Exhaled Breath Condensate Not Predictive for Exacerbations in Cystic Fibrosis
PLOS ONE | DOI:10.1371/journal.pone.0152156 April 6, 2016 11 / 13
5. Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax. 2007;
62(4):360–7. PMID: 17387214
6. Chmiel JF, Berger M, Konstan MW. The role of inflammation in the pathophysiology of CF lung disease.
Clin Rev Allergy Immunol. 2002; 23(1):5–27. PMID: 12162106
7. Nichols DP, Chmiel JF. Inflammation and its genesis in cystic fibrosis. Pediatr Pulmonol. 2015; 50
Suppl 40:S39–56. doi: 10.1002/ppul.23242 PMID: 26335954
8. Cooke G, Armstrong ME, Donnelly SC. Macrophage migration inhibitory factor (MIF), enzymatic activity
and the inflammatory response. Biofactors. 2009; 35(2):165–8. doi: 10.1002/biof.27 PMID: 19322762
9. Melotti P, Mafficini A, Lebecque P, Ortombina M, Leal T, Pintani E, et al. Impact of MIF gene promoter
polymorphism on F508del cystic fibrosis patients. PLoS One. 2014; 9(12):e114274. doi: 10.1371/
journal.pone.0114274 PMID: 25503271
10. Bodini A, D'Orazio C, Peroni D, Corradi M, Folesani G, Baraldi E, et al. Biomarkers of neutrophilic
inflammation in exhaled air of cystic fibrosis children with bacterial airway infections. Pediatr Pulmonol.
2005; 40(6):494–9. PMID: 16229003
11. van Mastrigt E, de Jongste JC, Pijnenburg MW. The analysis of volatile organic compounds in exhaled
breath and biomarkers in exhaled breath condensate in children—clinical tools or scientific toys? Clin
Exp Allergy. 2015; 45(7):1170–88. doi: 10.1111/cea.12454 PMID: 25394891
12. Robroeks CM, Rosias PP, van Vliet D, Jobsis Q, Yntema JB, Brackel HJ, et al. Biomarkers in exhaled
breath condensate indicate presence and severity of cystic fibrosis in children. Pediatr Allergy Immunol.
2008; 19(7):652–9. doi: 10.1111/j.1399-3038.2007.00693.x PMID: 18312532
13. Robroeks C, Jobsis Q, Braeckers R. Prediction of CF exacerbations by FeNO and non-invasive inflam-
matory markers in exhaled breath condensate. European Respiratory Society Congress; Berlin, Ger-
many: European Respiratory Journal; 2008. p. 540s.
14. Smyth AR, Bell SC, Bojcin S, Bryon M, Duff A, Flume P, et al. European Cystic Fibrosis Society Stan-
dards of Care: Best Practice guidelines. J Cyst Fibros. 2014; 13 Suppl 1:S23–42. doi: 10.1016/j.jcf.
2014.03.010 PMID: 24856775
15. Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, et al. Early
anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC
clinical trial and observational study'. Contemp Clin Trials. 2009; 30(3):256–68. doi: 10.1016/j.cct.2009.
01.003 PMID: 19470318
16. CBO. Richtlijn diagnostiek en behandeling van cystic fibrosis. 2007.
17. Flume PA, Mogayzel PJ Jr., Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, et al. Cystic fibrosis pul-
monary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009; 180
(9):802–8. doi: 10.1164/rccm.200812-1845PP PMID: 19729669
18. Klijn PH, van Stel HF, Quittner AL, van der Net J, DoelemanW, van der Schans CP, et al. Validation of
the Dutch cystic fibrosis questionnaire (CFQ) in adolescents and adults. J Cyst Fibros. 2004; 3(1):29–
36. PMID: 15463884
19. Rosias PP, Robroeks CM, van de Kant KD, Rijkers GT, Zimmermann LJ, van Schayck CP, et al. Feasi-
bility of a new method to collect exhaled breath condensate in pre-school children. Pediatr Allergy
Immunol. 2010; 21(1 Pt 2):e235–44. doi: 10.1111/j.1399-3038.2009.00909.x PMID: 19563465
20. Rosias PP, Robroeks CM, Kester A, den Hartog GJ, Wodzig WK, Rijkers GT, et al. Biomarker repro-
ducibility in exhaled breath condensate collected with different condensers. Eur Respir J. 2008; 31
(5):934–42. doi: 10.1183/09031936.00073207 PMID: 18184682
21. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirom-
etry. Eur Respir J. 2005; 26(2):319–38. PMID: 16055882
22. Molenberghs G VG. Models for Discrete Longitudinal Data. 1 ed: Springer-Verlag New York; 2005.
687 p.
23. Hastie T TR, Friedman J. The Elements of Statistical Learning. corrected edition ed. New York:
Springer; 2003.
24. Horak F Jr., Moeller A, Singer F, Straub D, Holler B, Helbich TH, et al. Longitudinal monitoring of pediat-
ric cystic fibrosis lung disease using nitrite in exhaled breath condensate. Pediatr Pulmonol. 2007; 42
(12):1198–206. PMID: 17968999
25. Bodini A, D'Orazio C, Peroni DG, Corradi M, Zerman L, Folesani G, et al. IL-8 and pH values in exhaled
condensate after antibiotics in cystic fibrosis children. Int J Immunopathol Pharmacol. 2007; 20(3):467–
72. PMID: 17880760
26. Colombo C, Faelli N, Tirelli AS, Fortunato F, Biffi A, Claut L, et al. Analysis of inflammatory and immune
response biomarkers in sputum and exhaled breath condensate by a multi-parametric biochip array in
cystic fibrosis. Int J Immunopathol Pharmacol. 2011; 24(2):423–32. PMID: 21658316
Biomarkers in Exhaled Breath Condensate Not Predictive for Exacerbations in Cystic Fibrosis
PLOS ONE | DOI:10.1371/journal.pone.0152156 April 6, 2016 12 / 13
27. Ojoo JC, Mulrennan SA, Kastelik JA, Morice AH, Redington AE. Exhaled breath condensate pH and
exhaled nitric oxide in allergic asthma and in cystic fibrosis. Thorax. 2005; 60(1):22–6. PMID:
15618578
28. Liou TG, Adler FR, Keogh RH, Li Y, Jensen JL, WalshW, et al. Sputum biomarkers and the prediction
of clinical outcomes in patients with cystic fibrosis. PLoS One. 2012; 7(8):e42748. doi: 10.1371/journal.
pone.0042748 PMID: 22916155
29. van Vliet D, Alonso A, Rijkers G, Heynens J, Rosias P, Muris J, et al. Prediction of asthma exacerba-
tions in children by innovative exhaled inflammatory markers: results of a longitudinal study. PLoS One.
2015; 10(3):e0119434. doi: 10.1371/journal.pone.0119434 PMID: 25799487
30. Sagel SD, Chmiel JF, Konstan MW. Sputum biomarkers of inflammation in cystic fibrosis lung disease.
Proc Am Thorac Soc. 2007; 4(4):406–17. PMID: 17652508
31. Robroeks CM, van Vliet D, Jobsis Q, Braekers R, Rijkers GT, Wodzig WK, et al. Prediction of asthma
exacerbations in children: results of a one-year prospective study. Clin Exp Allergy. 2012; 42(5):792–8.
doi: 10.1111/j.1365-2222.2012.03992.x PMID: 22515395
Biomarkers in Exhaled Breath Condensate Not Predictive for Exacerbations in Cystic Fibrosis
PLOS ONE | DOI:10.1371/journal.pone.0152156 April 6, 2016 13 / 13
